WCGI 2018 - New developments in Neuroendocrine cancer and Bile Duct Cancer in the last 12 Months


  • Carolina Rojido
  • Univadis
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Why this matters

  • Neuroendocrine cancer (NEC) incidence is increasing. Most common in the Netherlands and Canada and least in Japan and Taiwan.
  • Bile Duct Cancer (BDC) also a rare cancer with increasing incidence. Highest prevalence in Thailand, South Korea, China, Japan, Italy, and the UK. 

Key points

NEC:

  • New WHO tumor classification: G1 Ki-67 index changed to
  • TELESTAR/TELECAST: EMA approved telotistrat ethyl (Xermelo) for carcinoid syndrome diarrhea inadequately controlled by SSA. 
  • NETTER-1: in progressive midgut NET, EMA approved 177Lu-DOTATOC (Lutathera) for gastroenteropancreatic neuroendocrine tumors.
  • RADIANT-4: first study on QoL with Everolimus in non-functional GI or lung NET did not show improvement compared to placebo.  
  • Sunitinib phase IV trial: activity supported in advanced pancreatic NET.

BDC:

  • Adjuvant therapy phase III BCAT study showed no benefit from gemcitabine.
  • On advanced disease: Phase III FUGA-BT study showed gem/S1 is a new option for Japanese patients.
  • International Cancer Genome Consortium improved understanding of genetic environment of BDC: intra vs extra hepatic carcinomas have different mutation profiles (liver vs non liver associated, and inflammatory vs proliferative subclasses) which are tied to therapeutic and prognostic implications.

 

Please confirm your acceptance

To gain full access to GPnotebook please confirm:

By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.

Submit